Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Very Strong
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Neutral
Telephone
1.833.462.8482
Address
Suite 220 28159 Avenue Stanford Valencia, CA 91355
Description
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 2.34 - 5.62
Trade Value (12mth)
AU$233,008.00
1 week
-2.27%
1 month
1.57%
YTD
-37.53%
1 year
-46.58%
All time high
104.14
EPS 3 yr Growth
-31.90%
EBITDA Margin
-242.00%
Operating Cashflow
-$57m
Free Cash Flow Return
-44.40%
ROIC
-41.30%
Interest Coverage
-106.20
Quick Ratio
7.50
Shares on Issue (Fully Dilluted)
129m
HALO Sector
Healthcare
Next Company Report Date
20-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.24
Date | Announcements |
---|---|
05 September 24 |
Notification of cessation of securities - AVH
×
Notification of cessation of securities - AVH |
04 September 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
04 September 24 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
29 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
27 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
27 August 24 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
23 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
23 August 24 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
19 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
19 August 24 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
14 August 24 |
AVITA Medical Q2 2024 Investor Presentation
×
AVITA Medical Q2 2024 Investor Presentation |
09 August 24 |
Financial Results for Quarter Ending 30 June 2024
×
Financial Results for Quarter Ending 30 June 2024 |
09 August 24 |
AVITA Medical Reports Second Quarter Financial Results
×
AVITA Medical Reports Second Quarter Financial Results |
09 August 24 |
AVITA Medical Q2 2024 Earnings Slides
×
AVITA Medical Q2 2024 Earnings Slides |
09 August 24 |
AVITA Medical to Host Investor Webinar Briefing
×
AVITA Medical to Host Investor Webinar Briefing |
09 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
07 August 24 |
Statement of CDIs on issue - AVH
×
Statement of CDIs on issue - AVH |
06 August 24 |
Notification of cessation of securities - AVH
×
Notification of cessation of securities - AVH |
06 August 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
02 August 24 |
AVITA Medical Names Robin VanDenburgh as SVP of Sales
×
AVITA Medical Names Robin VanDenburgh as SVP of Sales |
01 August 24 |
AVITA Medical Expands Portfolio with Unique Dermal Matrix
×
AVITA Medical Expands Portfolio with Unique Dermal Matrix |
12 July 24 |
AVITA Medical to Announce Second Quarter 2024 Results
×
AVITA Medical to Announce Second Quarter 2024 Results |
10 July 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
10 July 24 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
09 July 24 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.